Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer

Yuko Matsubara, Keiichiro Nakamura, Hirofumi Matsuoka, Chikako Ogawa, Hisashi Masuyama

Research output: Contribution to journalArticle

Abstract

Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre-treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three-dimensional-CT (3D-CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D-CT can serve as an indicator of poor prognosis in patients with OC.

Original languageEnglish
Pages (from-to)376-382
Number of pages7
JournalMolecular and Clinical Oncology
Volume11
Issue number4
DOIs
Publication statusPublished - Oct 2019

Fingerprint

Skeletal Muscle
Sarcopenia
Disease-Free Survival
Survival
Tomography
Ovarian Neoplasms
Therapeutics
Cone-Beam Computed Tomography
Ovarian epithelial cancer
Neoplasms

Keywords

  • Low skeletal muscle mass
  • Ovarian cancer
  • Prognostic factor
  • Psoas area
  • Psoas major volume
  • Skeletal muscle area

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer. / Matsubara, Yuko; Nakamura, Keiichiro; Matsuoka, Hirofumi; Ogawa, Chikako; Masuyama, Hisashi.

In: Molecular and Clinical Oncology, Vol. 11, No. 4, 10.2019, p. 376-382.

Research output: Contribution to journalArticle

@article{0cf0941d37284006a1023659d1caa8f0,
title = "Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer",
abstract = "Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre-treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three-dimensional-CT (3D-CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D-CT can serve as an indicator of poor prognosis in patients with OC.",
keywords = "Low skeletal muscle mass, Ovarian cancer, Prognostic factor, Psoas area, Psoas major volume, Skeletal muscle area",
author = "Yuko Matsubara and Keiichiro Nakamura and Hirofumi Matsuoka and Chikako Ogawa and Hisashi Masuyama",
year = "2019",
month = "10",
doi = "10.3892/mco.2019.1912",
language = "English",
volume = "11",
pages = "376--382",
journal = "Molecular and Clinical Oncology",
issn = "2049-9450",
number = "4",

}

TY - JOUR

T1 - Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer

AU - Matsubara, Yuko

AU - Nakamura, Keiichiro

AU - Matsuoka, Hirofumi

AU - Ogawa, Chikako

AU - Masuyama, Hisashi

PY - 2019/10

Y1 - 2019/10

N2 - Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre-treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three-dimensional-CT (3D-CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D-CT can serve as an indicator of poor prognosis in patients with OC.

AB - Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre-treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three-dimensional-CT (3D-CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D-CT can serve as an indicator of poor prognosis in patients with OC.

KW - Low skeletal muscle mass

KW - Ovarian cancer

KW - Prognostic factor

KW - Psoas area

KW - Psoas major volume

KW - Skeletal muscle area

UR - http://www.scopus.com/inward/record.url?scp=85073392966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073392966&partnerID=8YFLogxK

U2 - 10.3892/mco.2019.1912

DO - 10.3892/mco.2019.1912

M3 - Article

AN - SCOPUS:85073392966

VL - 11

SP - 376

EP - 382

JO - Molecular and Clinical Oncology

JF - Molecular and Clinical Oncology

SN - 2049-9450

IS - 4

ER -